Atlas Trials

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Clinical trial NCT03357939 · COMPLETED

Trial details

NCT number
NCT03357939
Sponsor
Shanghai Henlius Biotech
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Immune System Disorder
Start date
2017-01-12
Primary completion
2018-09-15
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.